CHRONOTHERAPY OF HYPERTENSION: CURRENT STATE OF THE SCIENTIFIC PROBLEM
https://doi.org/10.20996/1819-6446-2017-13-5-706-715
Abstract
Recently, more and more attention has been paid to the chronotherapy of arterial hypertension (HT). This method provides an opportunity to improve the treatment efficacy by non-traditional regimes of antihypertensive drug intake. The new findings concerning a high prognostic value of the night-time blood pressure (BP) and night BP fall stimulate the interest in chronotherapy of HT. This method is very easy to use, and the evidences of its high efficacy are growing. The advantages and limitations of two potential chronotherapy approaches are discussed in detail.
MAPEC was the largest project which investigated the possibility of cardiovascular complications risk reduction by normalizing the circadian rhythm of BP due to the bed-time administration of antihypertensive drugs. The authors obtained impressive results – more than a double reduction of cardiovascular complications risk in the chronotherapy group. However, the study had serious limitations: ethnically homogeneous population, the lack of independent verification of endpoints and adverse events, and inconvenience of 48-hour BP monitoring.
The currently available scientific information concerning advantages of HT chronotherapy needs further confirmation in the carefully designed multi-centre prospective studies. According to the authors’ opinion, illustrated by their original data, the relatively small and short studies are still important. Such trials allow using more nuanced methodological approaches, such as a double blind or cross-over design and comparison of the pharmacokinetics of antihypertensive drugs in the morning and evening administration.About the Authors
V. M. Gorbunov
National Medical Research Center for Preventive Medicine
Russian Federation
Russian Federation
Vladimir M. Gorbunov – MD, PhD, Professor, Head of Laboratory of Outpatient Diagnostic Methods in the Prevention of Chronic Non-Communicable Diseases.
Petroverigsky per. 10, Moscow, 101990E. Y. Fedorova
National Medical Research Center for Preventive Medicine
Russian Federation
Russian Federation
Elena Y. Fedorova – MD, PhD, Researcher, Laboratory of Outpatient Diagnostic Methods in the Prevention of Chronic Non-Communicable Diseases.
Petroverigsky per. 10, Moscow, 101990E. V. Platonova
National Medical Research Center for Preventive Medicine
Russian Federation
Russian Federation
Elena V. Platonova – MD, PhD, Researcher, Laboratory of Outpatient Diagnostic Methods in the Prevention of Chronic Non-Communicable Diseases.
Petroverigsky per. 10, Moscow, 101990References
1. Lewington S., Clarke R., Qizilbash N. et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360(9349):1903-13. doi: 10.1016/S0140-6736(02)11911-8
2. Lawes C.M., Hoorn S.V., Rodgers A. Global burden of blood-pressure-related disease, 2001. Lancet. 2008;371(9623):1513-8. doi: 10.1016/S0140-6736(08)60655-8.
3. Kearney P., Whelton M., Reynolds K., et al. Worldwide prevalence of hypertension: a systematic review. J Hypertens. 2004;22:11-9.
4. Vorobjeva O.D, Denisenko M.B, Elizarov V.V, et al. The Demographic Yearbook of Russia. 2013: Statistical Handbook. Moscow: Rosstat; 2013. (In Russ.) [Воробьева О.Д., Денисенко М.Б., Елизаров В.В. и др. Демографический ежегодник России. Статистический сборник. М.: Росстат; 2013].
5. Boytsov S.A., Balanova Y.A., Shalnova S.A. et al. from participants ESSE-RF Trial. Hypertension in individuals of 25-64: prevalence, awareness, treatment and control. Cardiovascular Therapy and Prevention. 2014;13(4):4-14. (In Russ.) [Бойцов С. А., Баланова Ю. А., Шальнова С. А. и др. от имени участников исследования ЭССЕ-РФ. Артериальная гипертония среди лиц 25-64 лет: распространенность, осведомленность, лечение и контроль. По материалам исследования ЭССЕ. Кардиоваскулярная Терапия и Профилактика. 2014;13(4):4-14]. doi: 10.15829/1728-8800-2014-4-4-14
6. Bisognano J.D., Bakris G., Nadim M.K.et al. Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo controlledrheos pivotal trial. J Am Coll Cardiol. 2011;58(7):765-73. doi: 10.1016/j.jacc.2011.06.008.
7. Bakris G.L., Nadim M.K., Haller H. et al. Baroreflex activation therapy provides durable benefit in patients with resistant hypertension: results of long-term follow-up in the Rheos Pivotal Trial. J Am Soc Hypertens. 2012;6(2):152-8. doi: 10.1016/j.jash.2012.01.003.
8. Hoppe U.C., Brandt M.C., Wachter R. et al. Minimally invasive system for baroreflex activation therapy chronically lowers blood pressure with pacemaker-like safety profile: results from the Barostim Neo trial. J Am Soc Hypertens. 2012;6:270-6. doi: 10.1016/j.jash.2012.04.004.
9. Simplicity HTN-1 Investigators. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. Hypertension. 2011;57:911-7. doi: 10.1161/HYPERTENSIONAHA.110.163014.
10. Simplicity HTN-Investigators. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomized controlled trial. Lancet. 2010;376:1903-9. doi: 10.1016/S0140-6736(10)62039-9.
11. Gulat R., Raphael C.E., Negoita M. et al. The rise, fall, and possible resurrection of renal denervation. Nat Rev Cardiol. 2016;13(4):238-44. doi: 10.1038/nrcardio.2016.1.
12. Olbinskaya L.I., Hapaev B.A. Chronotherapy aspects of application of different forms of nifedipine in hypertensive patients. Kardiologiia. 2000;6:59-62. (In Russ.) [Ольбинская Л.И., Хапаев Б.А. Хронотерапевтические аспекты применения различных форм нифедипина у больных гипертонической болезнью. Кардиология. 2000;6:59-62].
13. Smolensky M.H., Hermida R.C., Ayala D.E. et al. Administration-time-dependent effects of blood pressure-lowering medications: basis for the chronotherapy of hypertension. Blood Press Monit. 2010;15:173-80. doi: 10.1097/MBP.0b013e32833c7308.
14. White W.B. Circadian variation of blood pressure and the assessment of antihypertensive therapy. Blood Press Monit. 1999;4(1):3-6.
15. Hansen T.W. et al. Predictive role of the night-time blood pressure. Hypertension. 2011;57(1):3-10. doi: 10.1161/HYPERTENSIONAHA.109.133900.
16. Olbinskaya L.I., Martynov A.I., Hapaev B.A. Blood pressure monitoring in cardiology. Moscow: ID «Russkij vrach»; 1998. (In Russ.) [Ольбинская Л.И., Мартынов А.И., Хапаев Б.А. Мониторирование артериального давления в кардиологии. М.: ИД «Русский врач»; 1998].
17. Gorbunov V.M., Oganov R.G., Deev A.D. Comparative relevance of different methods of ambulatory blood pressure analysis in antihypertensive treatment. Cardiovascular Therapy and Prevention. 2003;2(1):17-26. (In Russ.) [Горбунов В.М., Оганов Р.Г., Деев А.Д. Сравнительная информативность различных способов анализа результатов суточного мониторирования артериального давления в оценке эффективности антигипертензивной терапии. Кардиоваскулярная Терапия и Профилактика. 2003;2(1):17-26].
18. Ohkubo T., Hozawa A., Yamaguchi J.et al. Prognostic significance of the nocturnal decline in blood pressure in individuals with and without high 24-h blood pressure: the Ohasama study. J Hypertens. 2002;20:2183-9.
19. Hoshide S., Kario K., Hoshide Y.et al. Associations between non-dipping of nocturnal blood pressure decrease and cardiovascular target organ damage in strictly selected community-dwelling normotensives. Am J Hypertens. 2003;16:434-8. doi: 10.1016/S0895-7061(03)00567-3
20. Dolan E., Stanton A., Thijs L. et al. Superiority of ambulatory over clinic blood pressure measurement in predicting mortality: the Dublin outcome study. Hypertension. 2005;46:156-61. doi: 10.1161/01.HYP.0000170138.56903.7a
21. Mancia G., Facchetti R., Bombelli M. et al. Long-term risk of mortality associated with selective and combined elevation in office, home, and ambulatory blood pressure. Hypertension. 2006;47:846-53. doi: 10.1161/01.HYP.0000215363.69793.bb
22. Verdecchia P., Porcellati C., Schillaci G.et al. Ambulatory blood pressure: an independent predictor of prognosis in essential hypertension. Hypertension. 1994;24:793-801.
23. Staessen J.A., Thijs L., Fagard R.et al. for the Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Predicting cardiovascular risk using conventional vs. ambulatory blood pressure in older patients with systolic hypertension. JAMA. 1999;282:539-46.
24. Yamamoto Y., Akiguchi I., Oiwa K. et al. Adverse effect of nighttime blood pressure on the outcome of lacunar infarct patients. Stroke. 1998;29:570-6.
25. Schillaci G., Battista F., Settimi L.et al. Antihypertensive Drug Treatment and Circadian Blood Pressure Rhythm: A Review of the Role of Chronotherapy in Hypertension. Current Pharmaceutical Design. 2015;21:756-72. doi: 10.2174/1381612820666141024130013
26. Henskens L.H., Kroon A.A., van Oostenbrugge R.J.et al. Different classifications of nocturnal blood pressure dipping affect the prevalence of dippers and non-dippers and the relation with target-organ damage. J Hypertens. 2008;26:691-8. doi: 10.1097/HJH.0b013e3282f4225f.
27. Van Ittersum F.J., Ijzerman R.G., Stehouwer CD.A., Donker A.J.M. Analysis of twenty-four-hour ambulatory blood pressure monitoring: what time period to assess blood pressures during waking and sleeping? J Hypertens. 1995;13:1053-8.
28. Kario K. Clinician's Manual on Early Morning Risk Management in Hypertension. London , UK: Current Medicine Group Ltd. 2005.
29. Kario K. Morning Surge in Blood Pressure and Cardiovascular Risk. Evidence and Perspectives. Hypertension. 2010;56:765 -73. doi: 10.1161/HYPERTENSIONAHA.110.157149.
30. O’Brien E., Parati G., Stergiou G. et al. on behalf of the European Society of Hypertension Working Group on Blood Pressure Monitoring Ambulatory blood. European Society of Hypertension Position Paper on Ambulatory Blood Pressure Monitoring. Journal of Hypertension. 2013;31:1731-68. doi: 10.1097/HJH.0b013e328363e964.
31. Hoshide S., Kario K., de la Sierra A. et al. Ethnic differences in the degree of morning blood pressure. Surge and in its determinants between Japanese and European hypertensive subjects data from the ARTEMIS Study. Hypertension. 2015;66(4):750-6. doi: 10.1161/HYPERTENSIONAHA.115.05958.
32. Hermida R. C., Diana E.A., Smolensky M.H. et al. Chronotherapy with conventional blood pressure medications improves management of hypertension and reduces cardiovascular and stroke risks. Hypertens Res. 2016;39(5):277-92. doi: 10.1038/hr.2015.142.
33. Hermida R.C., Ayala D.E., Mojón A., FernЗndez J.R. Bedtime ingestion of hypertension medications reduces of new-onset type 2 diabetes: a randomized controlled trial. Diabetologia. 2015;59(2):395-405. doi: 10.1007/s00125-015-3749-7.
34. Hermida R.C. Аmbulatory blood pressure monitoring in the prediction of cardiovascular events and effects of chronotherapy: rationale and design of the MAPEC. Chronobiol Int. 2007;24(4):749-75. doi: 10.1080/07420520701535837.
35. Hermida R.C, Smolensky M.H., Ayala D.E., Portaluppi F. 2013 ambulatory blood pressure monitoring recommendation for diagnosis of adult hypertension assessment of cardiovascular and other hypertension-associated risk, and attainment of therapeutic goals. Chronobiol Int. 2013;30(3):355-410. doi: 10.3109/07420528.2013.750490.
36. Joint recommendations of the International Society of Chronobiology (ISC), the American Association of Medical Chronobiology and Chronotherapy (AAMSS), the Spanish Society for Applied Chronobiology, Chronotherapy and Vascular Risk (SECAC), the Spanish Society of Atherosclerosis (SEA) and the Romanian Society for Internal Medicine (RSIM). Nizhny Novgorod: Dekom; 2015. (In Russ.) [Совместные рекомендации Международного общества Хронобиологии (ISC), Американской ассоциации медицинской хронобиологии и хронотерапии (ААМСС), Испанского общества прикладной хронобиологии, хронотерапии и сосудистого риска (SECAC), испанского общества атеросклероза(SEA) и Румынского общества по внутренним болезням (RSIM). Нижний Новгород: Деком; 2015].
37. Stranges P., Drew A.M., Rafferty P.et al. Treatment of Hypertension With Chronotherapy. Is It Time? Annals of Pharmacotherapy. 2014;1(12):1-12. doi: 10.1177/1060028014563535.
38. James P.A., Oparil S., Carter B.L. et al. 2014 Evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint. JAMA. 2014 Feb 5;311(5):507-20. doi: 10.1001/jama.2013.284427.
39. Chobanian A.V., Bakris G.L., Black H.R. et al. The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA. 2003;289:2560-72. doi: 10.1001/jama.289.19.2560.
40. Go A.S., Bauman M., King S.M. et al. An effective approach to high blood pressure control: a science advisory from the American Heart Association, the American College of Cardiology, and the Centers for Disease Control and Prevention. Hypertension. 2014;63:878-85. doi: 10.1161/HYP.0000000000000003.
41. Mancia G., Fagard R., Narkiewicz K. et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34:2159-219. doi: 10.1093/eurheartj/eht151.
42. Weber M.A., Schiffrin E.L., White W.B. et al. Clinical practice guidelines for the management of hypertension in the community a statement by the American Society of Hypertension and the International Society of Hypertension. J Hypertens. 2014;32:3-15. doi: 10.1097/HJH.0000000000000065.
43. Lindsay .P, Connor Gorber S., Joffres M. et al. Recommendations on screening for high blood pressure in Canadian adults. Can Fam Physician. 2013;59:927-33.
44. Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO clinical practice guidelines for the management of blood pressure in chronic kidney disease. Kidney Int Suppl. 2012;2:337-414. doi: 10.1038/kisup.2012.46
45. American Diabetes Association. Standards of medical care in diabetes 2014. Diabetes Care. 2014;37(1):14-80. doi: 10.2337/dc14-S014.
46. Standards of Medical Care in Diabetes -2015. Diabetes Care. 2015;38(1):1-87. doi: 10.2337/dc15-S003.
47. Calhoun D.A., Jones D., Textor S. et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education. Committee of the Council for High Blood Pressure Research. Hypertension. 2008;51:1403-19. doi: 10.1161/CIRCULATIONAHA.108.189141.
48. Carter B.L., Chrischilles E.A., Rosenthal G. et al. Efficacy and safety of nighttime dosing of antihypertensive: review of the literature and design of a pragmatic clinical trial. J Clin Hypertens (Greenwich). 2014;16:115-21. doi: 10.1111/jch.12238.
49. Parati G. Blood pressure reduction at night: sleep and beyond. J Hypertens. 2000;18:1725-9.
50. Rorie D.A., Rogers A., Mackenzie I.S. et al. Methods of a large prospective, randomized, open-label, blinded end-point study comparing morning versus evening dosing in hypertensive patients: the Treatment In Morning versus Evening (TIME) study. BMJ Open. 2016;6(2):1-10. doi: 10.1136/bmjopen-2015-010313.
51. Belolipetskaya V.G., Guranda D.F., Fedorova E.Yu. et al. Chronopharmacology of verapamil in Stage I-II arterial hypertension. Cardiovascular Therapy and Prevention. 2009;8:13-8. (In Russ.) [Белолипецкая В.Г., Гуранда Д.Ф., Федорова Е.Ю. и др. Хронофармакокинетика верапамила у больных АГ I-II степени. Кардиоваскулярная Терапия и Профилактика. 2009;8:13-8].
52. Gorbunov V.M., Fedorova E.J., Deev A.D.et al. Effect of morning and evening ramipril prescription on ambulatory blood pressure patterns in patients with hypertension. Rational Pharmacotherapy in Cardiology. 2009;1:28-32. (In Russ.) [Горбунов В.М., Федорова Е.Ю., Деев А.Д. и др. Влияние утреннего и вечернего назначения рамиприла на суточный профиль артериального давления у больных с артериальной гипертонией. Рациональная Фармакотерапия в Кардиологии. 2009;1:28-32]. doi: 10.20996/1819-6446-2009-5-1-28-32
53. Zuther P., Witte K., Lemmer B. ABPM-FIT and CV-SORT: an easy-to-use software package for detailed analysis of data from ambulatory blood pressure monitoring. Blood Press Monit. 1996; 1:347-54.
54. Poulter N., Anjum A., Cross M. et al. Comparison of the impact of morning or night delivery of antihypertensive agent on 24 hour ABPM levels: a randomized cross-over trial (HARMONY). J Hypertens. 2016;34(1):547. doi: 10.1111/jth.13213.
Review
For citations:
Gorbunov V.M., Fedorova E.Y., Platonova E.V. CHRONOTHERAPY OF HYPERTENSION: CURRENT STATE OF THE SCIENTIFIC PROBLEM. Rational Pharmacotherapy in Cardiology. 2017;13(5):706-715. (In Russ.) https://doi.org/10.20996/1819-6446-2017-13-5-706-715
Views:
1317
.jpg)
Email this article 